(Q37782569)

23 August 2017

title

Recent advances in histone deacetylase targeted cancer therapy (English)

1 reference

23 August 2017

Isamu Hoshino

1

1 reference

23 August 2017

Hisahiro Matsubara

series ordinal

2

1 reference

23 August 2017

publication date

26 August 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

40

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

809-815

1 reference

The epigenome as a target for cancer chemoprevention

23 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00595-010-4300-6

Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00595-010-4300-6

A novel tetracyclic peptide, trapoxin, induces phenotypic change from transformed to normal in sis-oncogene-transformed NIH3T3 cells

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00595-010-4300-6

CpG island methylation in precursors of gastrointestinal malignancies

21 January 2018

1 reference

12 December 2020

Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis

1 reference

12 December 2020

Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB.

1 reference

12 December 2020

Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas

1 reference

12 December 2020

Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.

1 reference

12 December 2020

Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells.

1 reference

12 December 2020

Class II histone deacetylases: versatile regulators

1 reference

12 December 2020

Epigenetic changes in solid and hematopoietic tumors.

1 reference

12 December 2020

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

1 reference

12 December 2020

Expression profile of class I histone deacetylases in human cancer tissues.

1 reference

12 December 2020

Clinical development of histone deacetylase inhibitors as anticancer agents

1 reference

12 December 2020

The molecular biology of esophageal adenocarcinoma.

1 reference

12 December 2020

Review article: the stages of gastrointestinal carcinogenesis--application of rodent models to human disease

1 reference

12 December 2020

Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.

1 reference

12 December 2020

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

1 reference

12 December 2020

Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives

1 reference

12 December 2020

Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug

1 reference

12 December 2020

Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.

1 reference

12 December 2020

Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase

1 reference

12 December 2020

A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p

1 reference

12 December 2020

p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells

1 reference

12 December 2020

Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors

1 reference

12 December 2020

Impact of novel histone deacetylase inhibitors, CHAP31 and FR901228 (FK228), on adenovirus-mediated transgene expression

1 reference

12 December 2020

Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells

1 reference

12 December 2020

Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns

1 reference

12 December 2020

Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells

1 reference

12 December 2020

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms

1 reference

12 December 2020

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias

1 reference

12 December 2020

Targeting histone deacetylase in cancer therapy

1 reference

12 December 2020

Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas

1 reference

12 December 2020

Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors

1 reference

12 December 2020

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

1 reference

12 December 2020

Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway

1 reference

12 December 2020

The consensus coding sequences of human breast and colorectal cancers

1 reference

12 December 2020

Rational development of histone deacetylase inhibitors as anticancer agents: a review

1 reference

12 December 2020

The human histone deacetylase family

1 reference

12 December 2020

Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.

1 reference

12 December 2020

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

1 reference

12 December 2020

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity

1 reference

12 December 2020

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

1 reference

12 December 2020

Lung cancer epigenetics and genetics

1 reference

12 December 2020

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study

1 reference

12 December 2020

Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer

1 reference

12 December 2020

A phase II study of depsipeptide in refractory metastatic renal cell cancer

1 reference

12 December 2020

Expression of HDAC1 and CBP/p300 in human colorectal carcinomas

1 reference

12 December 2020

Histone deacetylase inhibitors

1 reference

12 December 2020

Epigenetics in bladder cancer

1 reference

12 December 2020

Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin

1 reference

12 December 2020

Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial

1 reference

12 December 2020

Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides

1 reference

12 December 2020

Depsipeptide-resistant KU812 cells show reversible P-glycoprotein expression, hyper-acetylated histones, and modulated gene expression profile

1 reference

12 December 2020

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study

1 reference

12 December 2020

Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors

1 reference

12 December 2020

Clinical and molecular responses in lung cancer patients receiving Romidepsin

1 reference

12 December 2020

Histone deacetylase inhibitors: from target to clinical trials

1 reference

12 December 2020

FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases

1 reference

12 December 2020

Simple inhibitors of histone deacetylase activity that combine features of short-chain fatty acid and hydroxamic acid inhibitors

1 reference

12 December 2020

Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas

1 reference

12 December 2020

FDG-PET/CT for the evaluation of response to therapy of cutaneous T-cell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial

1 reference

12 December 2020

Role of histone deacetylase inhibitor in adenovirus-mediated p53 gene therapy in esophageal cancer.

1 reference

12 December 2020

Molecular analysis of a candidate metastasis-associated gene, MTA1: possible interaction with histone deacetylase 1.

1 reference

12 December 2020

Chromatin-remodelling mechanisms in cancer.

1 reference

12 December 2020

Cooperation between complexes that regulate chromatin structure and transcription

1 reference

12 December 2020

Apicidin, a histone deacetylase inhibitor, induces differentiation of HL-60 cells

1 reference

12 December 2020

Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function

1 reference

12 December 2020

Sodium butyrate enhances Fas-mediated apoptosis of human hepatoma cells

1 reference

12 December 2020

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

1 reference

12 December 2020

HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics

1 reference

12 December 2020

10.1007/S00595-010-4300-6

Identifiers

DOI

1 reference

23 August 2017

1 reference